PARP1 and atrial fibrillation: These findings not only indicate a novel mechanism by which AF impairs atrial cardiomyocyte function, but also indicate PARP1-inhibition, NAD+ supplementation and/or microtubule conservation as a possible therapeutic target that may preserve atrial cardiomyocyte function in clinical AF.